%0 Journal Article
%T Effect of Sodium-Glucose Co-Transporter-2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction.
%A Taťána A
%A Filip M
%J Clin Cardiol
%V 47
%N 7
%D 2024 Jul
%M 39031990
%F 3.287
%R 10.1002/clc.24303
%X <B>BACKGROUND: </B>The increased diuresis after sodium-glucose cotransporter 2 inhibitor (SGLT2i) was associated with a reduction of the estimated plasma volume (ePV) in type 2 diabetic patients.<BR><B>OBJECTIVE: </B>We hypothesized that the early effect of SGLT2i on ePV may be monitored by the change of biomarkers of hemoconcentration.<BR><B>METHODS: </B>We analyzed the early- and long-term effect of SGLT2i empagliflozin on the ePV as assessed by biomarkers of hemoconcentration in a nondiabetic patient with heart failure and reduced ejection fraction (HFrEF) and a nondiabetic patient with heart failure and preserved ejection fraction (HFpEF). The ePV was calculated from hemoglobin and hematocrit levels by Duarte formula and ePV change was calculated by Strauss formula.<BR><B>RESULTS: </B>The ePV change was -22.56% between baseline and 1 month, and -37.60% between baseline and 12 months follow-up in a patient with HFrEF, and -6.18% and -16.40% in a patient with HFpEF, respectively.<BR><B>CONCLUSIONS: </B>The early effect of SGLT2i on ePV in patients with heart failure may be monitored by biomarkers of hemoconcentration.